Mepolizumab Showing Promise for High-Risk Eosinophilic COPD Mepolizumab Showing Promise for High-Risk Eosinophilic COPD

A biologic that targets interleukin-5 could reduce COPD exacerbations in patients with high blood eosinophil counts, new research shows.Medscape Medical News
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Pulmonary Medicine News Source Type: news